Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Immunotherapy to Treat Advanced Prostate Cancer

ClinicalTrials.gov ID: NCT00861614

Public ClinicalTrials.gov record NCT00861614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone

Study identification

NCT ID
NCT00861614
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
988 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2009
Primary completion
Oct 31, 2012
Completion
Jul 31, 2015
Last update posted
Sep 29, 2016

2009 – 2015

United States locations

U.S. sites
44
U.S. states
24
U.S. cities
42
Facility City State ZIP Site status
Southern Cancer Center Mobile Alabama 36608 —
Alaska Clinical Research Center, Llc Anchorage Alaska 99508 —
Arizona Clinical Research Center, Inc. Tucson Arizona 85715 —
Highlands Oncology Group, P.A. Fayetteville Arkansas 72703 —
Marsha G. Fink, Md, Inc. Fountain Valley California 92708 —
Loma Linda University Cancer Center Loma Linda California 92350 —
Usc/Norris Comprehensive Cancer Center Los Angeles California 90033 —
Prostate Oncology Specialists, Inc. Marina del Rey California 90292 —
Comprehensive Cancer Center Palm Springs California 92262 —
Va San Diego Healthcare System San Diego California 92161 —
Pacific Hematology Oncology Associates San Francisco California 94115 —
Baptist Cancer Institute Jacksonville Florida 32207 —
Orlando Health, Inc Orlando Florida 32806 —
Suburban Hematology-Oncology Associates, Pc Lawrenceville Georgia 30046 —
University Of Chicago Chicago Illinois 60637 —
Cancer Care Specialists Of Central Illinois Decatur Illinois 62526 —
Edward Cancer Center Naperville Illinois 60540 —
Mid-Illinois Hematology & Oncology Associates, Ltd Normal Illinois 61761 —
University Of Iowa Hospitals And Clinics Iowa City Iowa 52242 —
Siouxland Hematology-Oncology Assoc., Llp Sioux City Iowa 51101 —
Hutchinson Clinic, Pa Hutchinson Kansas 67502 —
Kentucky Cancer Clinic Hazard Kentucky 41701 —
The Bunting-Blaustein Cancer Research Building Baltimore Maryland 21231 —
Frederick Memorial Hospital Regional Cancer Therapy Center Frederick Maryland 21701 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
Mayo Clinic Rochester Minnesota 55905 —
Kansas City Veterans Affairs Medical Center Kansas City Missouri 64128 —
St Johns Medical Research Institute, Inc. Springfield Missouri 65807 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Weill Cornell Medical College New York New York 10065 —
Raleigh Hematology Oncology Associates Raleigh North Carolina 27607 —
Gabrail Cancer Center Canton Ohio 44718 —
University Of Cincinnati Cincinnati Ohio 45267 —
Providence Portland Medical Center Portland Oregon 97213 —
St. Luke'S Hospital & Health Network Laboratory Bethlehem Pennsylvania 18015 —
Va Pittsburgh Healthcare System Pittsburgh Pennsylvania 15240 —
Associates In Hematology & Oncology, P.C. Upland Pennsylvania 19013 —
Musc Hollings Cancer Center Charleston South Carolina 29445 —
Center For Oncology Research & Treatment, P.A. Dallas Texas 75230 —
The Center For Cancer And Blood Disorders Fort Worth Texas 76104 —
The University Of Texas Md Anderson Cancer Center Houston Texas 77030 —
Northwest Cancer Center Houston Texas 77090 —
Huntsman Cancer Institute Salt Lake City Utah 84112 —
Edwards Comprehensive Cancer Center Huntington West Virginia 25701 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00861614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 29, 2016 · Synced Sep 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00861614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →